Compare ALEMBIC PHARMA with Piramal Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PIRAMAL ENTERPRISES ALEMBIC PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 16.6 -35.0 - View Chart
P/BV x 6.6 1.2 559.1% View Chart
Dividend Yield % 0.6 2.0 29.4%  

Financials

 ALEMBIC PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
PIRAMAL ENTERPRISES
Mar-19
ALEMBIC PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs6643,303 20.1%   
Low Rs4121,797 23.0%   
Sales per share (Unadj.) Rs208.7716.5 29.1%  
Earnings per share (Unadj.) Rs31.079.7 38.9%  
Cash flow per share (Unadj.) Rs37.1107.9 34.4%  
Dividends per share (Unadj.) Rs5.5028.00 19.6%  
Dividend yield (eoy) %1.01.1 93.1%  
Book value per share (Unadj.) Rs144.21,477.5 9.8%  
Shares outstanding (eoy) m188.52184.45 102.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.63.6 72.5%   
Avg P/E ratio x17.432.0 54.3%  
P/CF ratio (eoy) x14.523.6 61.4%  
Price / Book Value ratio x3.71.7 216.3%  
Dividend payout %17.735.1 50.5%   
Avg Mkt Cap Rs m101,461470,292 21.6%   
No. of employees `000NA7.8 0.0%   
Total wages/salary Rs m7,46722,504 33.2%   
Avg. sales/employee Rs ThNM16,899.4-  
Avg. wages/employee Rs ThNM2,877.7-  
Avg. net profit/employee Rs ThNM1,879.9-  
INCOME DATA
Net Sales Rs m39,347132,153 29.8%  
Other income Rs m943,128 3.0%   
Total revenues Rs m39,441135,281 29.2%   
Gross profit Rs m8,73666,290 13.2%  
Depreciation Rs m1,1525,202 22.2%   
Interest Rs m18444,097 0.4%   
Profit before tax Rs m7,49320,119 37.2%   
Minority Interest Rs m113,194 0.3%   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5688,611 18.2%   
Profit after tax Rs m5,84414,701 39.7%  
Gross profit margin %22.250.2 44.3%  
Effective tax rate %20.942.8 48.9%   
Net profit margin %14.911.1 133.5%  
BALANCE SHEET DATA
Current assets Rs m19,577122,742 15.9%   
Current liabilities Rs m14,896310,810 4.8%   
Net working cap to sales %11.9-142.3 -8.4%  
Current ratio x1.30.4 332.8%  
Inventory Days Days9023 389.0%  
Debtors Days Days4539 116.8%  
Net fixed assets Rs m27,097116,904 23.2%   
Share capital Rs m377369 102.2%   
"Free" reserves Rs m26,811272,161 9.9%   
Net worth Rs m27,188272,530 10.0%   
Long term debt Rs m4,993270,196 1.8%   
Total assets Rs m47,778856,261 5.6%  
Interest coverage x41.71.5 2,863.7%   
Debt to equity ratio x0.21.0 18.5%  
Sales to assets ratio x0.80.2 533.6%   
Return on assets %12.66.9 183.7%  
Return on equity %21.55.4 398.4%  
Return on capital %23.612.4 190.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45315,200 128.0%   
Fx outflow Rs m6,0654,889 124.1%   
Net fx Rs m13,38810,312 129.8%   
CASH FLOW
From Operations Rs m8,120-115,975 -7.0%  
From Investments Rs m-7,556-8,265 91.4%  
From Financial Activity Rs m590107,525 0.5%  
Net Cashflow Rs m1,153-16,650 -6.9%  

Share Holding

Indian Promoters % 74.1 52.9 140.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 4.0 72.5%  
FIIs % 9.1 26.6 34.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 16.5 84.2%  
Shareholders   49,328 93,274 52.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 500 Points Lower; Dow Futures Down by 77 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 553 points, down 1.1% at 47,794 levels.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 27, 2021 03:36 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS